title: Rethinking the appraisal and approval of drugs for type 2 diabetes.
authors.affiliation: LSE Health, Department of Social Policy, London School of Economics and Political Science, London, UK h.naci@lse.ac.uk.
authors.forename: Huseyin
authors.initials: H
authors.lastname: Naci
authors.affiliation: Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
authors.forename: Richard
authors.initials: R
authors.lastname: Lehman
authors.affiliation: LSE Health, Department of Social Policy, London School of Economics and Political Science, London, UK.
authors.forename: Olivier J
authors.initials: OJ
authors.lastname: Wouters
authors.affiliation: Centre for Evidence Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford.
authors.forename: Ben
authors.initials: B
authors.lastname: Goldacre
authors.affiliation: Division of Medicine, University College London, London, UK.
authors.forename: John S
authors.initials: JS
authors.lastname: Yudkin
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D017277:Drug Approval / Q000458:organization & administration*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*
chemical_list: D007004:Hypoglycemic Agents